BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24658009)

  • 21. Expression of the epigenetic factor BORIS (CTCFL) in the human genome.
    de Necochea-Campion R; Ghochikyan A; Josephs SF; Zacharias S; Woods E; Karimi-Busheri F; Alexandrescu DT; Chen CS; Agadjanyan MG; Carrier E
    J Transl Med; 2011 Dec; 9():213. PubMed ID: 22168535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BORIS/CTCFL expression activates the TGFβ signaling cascade and induces Drp1 mediated mitochondrial fission in neuroblastoma.
    Makani VKK; Mendonza JJ; Edathara PM; Yerramsetty S; Pal Bhadra M
    Free Radic Biol Med; 2021 Nov; 176():62-72. PubMed ID: 34534628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma.
    Loukinov DI; Pugacheva E; Vatolin S; Pack SD; Moon H; Chernukhin I; Mannan P; Larsson E; Kanduri C; Vostrov AA; Cui H; Niemitz EL; Rasko JE; Docquier FM; Kistler M; Breen JJ; Zhuang Z; Quitschke WW; Renkawitz R; Klenova EM; Feinberg AP; Ohlsson R; Morse HC; Lobanenkov VV
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6806-11. PubMed ID: 12011441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
    Alberti L; Losi L; Leyvraz S; Benhattar J
    PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MAGEA1 inhibits the expression of BORIS via increased promoter methylation.
    Zhao J; Wang Y; Liang Q; Xu Y; Sang J
    J Cell Sci; 2019 Jan; 132(1):. PubMed ID: 30498011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.
    Debruyne DN; Dries R; Sengupta S; Seruggia D; Gao Y; Sharma B; Huang H; Moreau L; McLane M; Day DS; Marco E; Chen T; Gray NS; Wong KK; Orkin SH; Yuan GC; Young RA; George RE
    Nature; 2019 Aug; 572(7771):676-680. PubMed ID: 31391581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The epigenetic factor BORIS/CTCFL regulates the NOTCH3 gene expression in cancer cells.
    Zampieri M; Ciccarone F; Palermo R; Cialfi S; Passananti C; Chiaretti S; Nocchia D; Talora C; Screpanti I; Caiafa P
    Biochim Biophys Acta; 2014 Sep; 1839(9):813-25. PubMed ID: 24984200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BORIS/CTCFL epigenetically reprograms clustered CTCF binding sites into alternative transcriptional start sites.
    Pugacheva EM; Bhatt DN; Rivero-Hinojosa S; Tajmul M; Fedida L; Price E; Ji Y; Loukinov D; Strunnikov AV; Ren B; Lobanenkov VV
    Genome Biol; 2024 Jan; 25(1):40. PubMed ID: 38297316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis.
    Liao X; Siu MK; Chan KY; Wong ES; Ngan HY; Chan QK; Li AS; Khoo US; Cheung AN
    Int J Cancer; 2008 Jul; 123(2):296-302. PubMed ID: 18404674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Lesions of Insulator CTCF and Its Paralogue CTCFL (BORIS) in Cancer: An Analysis from Published Genomic Studies.
    Voutsadakis IA
    High Throughput; 2018 Oct; 7(4):. PubMed ID: 30275357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CTCFL (BORIS) mRNA Expression in a Peripheral Giant Cell Granuloma of the Oral Cavity.
    Zambrano-Galván G; Reyes-Romero M; Bologna-Molina R; Almeda-Ojeda OE; Lemus-Rojero O
    Case Rep Dent; 2014; 2014():792615. PubMed ID: 25114808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A polymorphic minisatellite region of BORIS regulates gene expression and its rare variants correlate with lung cancer susceptibility.
    Yoon SL; Roh YG; Chu IS; Heo J; Kim SI; Chang H; Kang TH; Chung JW; Koh SS; Larionov V; Leem SH
    Exp Mol Med; 2016 Jul; 48(7):e246. PubMed ID: 27416782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Widespread expression of BORIS/CTCFL in normal and cancer cells.
    Jones TA; Ogunkolade BW; Szary J; Aarum J; Mumin MA; Patel S; Pieri CA; Sheer D
    PLoS One; 2011; 6(7):e22399. PubMed ID: 21811597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CTCF and CTCFL in cancer.
    Debaugny RE; Skok JA
    Curr Opin Genet Dev; 2020 Apr; 61():44-52. PubMed ID: 32334335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells.
    Tiffen JC; Bailey CG; Marshall AD; Metierre C; Feng Y; Wang Q; Watson SL; Holst J; Rasko JE
    Int J Cancer; 2013 Oct; 133(7):1603-13. PubMed ID: 23553099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cancer-associated CTCFL/BORIS protein targets multiple classes of genomic repeats, with a distinct binding and functional preference for humanoid-specific SVA transposable elements.
    Pugacheva EM; Teplyakov E; Wu Q; Li J; Chen C; Meng C; Liu J; Robinson S; Loukinov D; Boukaba A; Hutchins AP; Lobanenkov V; Strunnikov A
    Epigenetics Chromatin; 2016; 9(1):35. PubMed ID: 27588042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Down-regulation of BORIS/CTCFL efficiently regulates cancer stemness and metastasis in MYCN amplified neuroblastoma cell line by modulating Wnt/β-catenin signaling pathway.
    Garikapati KR; Patel N; Makani VKK; Cilamkoti P; Bhadra U; Bhadra MP
    Biochem Biophys Res Commun; 2017 Feb; 484(1):93-99. PubMed ID: 28104398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CTCF and BORIS in genome regulation and cancer.
    Marshall AD; Bailey CG; Rasko JE
    Curr Opin Genet Dev; 2014 Feb; 24():8-15. PubMed ID: 24657531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent patterns of DNA methylation in the ZNF154, CASP8, and VHL promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines.
    Sánchez-Vega F; Gotea V; Petrykowska HM; Margolin G; Krivak TC; DeLoia JA; Bell DW; Elnitski L
    Epigenetics; 2013 Dec; 8(12):1355-72. PubMed ID: 24149212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BORIS/CTCFL-mediated chromatin accessibility alterations promote a pro-invasive transcriptional signature in melanoma cells.
    Moscona R; Janssen SM; Elchebly M; Papadakis AI; Rubin E; Spatz A
    Pigment Cell Melanoma Res; 2023; 36(3-4):299-313. PubMed ID: 37082838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.